Homeless Youth Study - Stepping Stone Project

August 6, 2018 updated by: Alyson Zalta, Rush University Medical Center

Using Smartphone Technology to Provide Mental Health Interventions for Homeless Youth

Homelessness is associated with a multitude of negative consequences including an increased risk for mental health problems. Once homeless, these individuals face significant barriers to mental health care and are therefore less likely to receive the treatment they need. Mobile technology may offer a novel platform for increasing access to mental health care in this population. Thus, the primary goals of this pilot study are to (1) establish the feasibility and acceptability of delivering a brief cognitive-behavioral intervention to homeless youth via smartphone technology, (2) examine the extent to which brief cognitive-behavioral interventions delivered via mobile technology improve mental health and trauma-related psychological symptoms in homeless youth, and (3) establish smartphone usage patterns among homeless youth to inform future interventions.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

35

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 23 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • English-speaking
  • Homeless as defined by lacking "a fixed, regular, and adequate nighttime residence," (Department of Education) including youth who temporarily share the housing of others due to financial hardship
  • Currently sleeping in a Chicago-based shelter (at least 50% of nights in the past week)
  • Willingness and ability to comply with requirements of the study protocol

Exclusion Criteria:

  • Involvement in risky behaviors that could interfere with the ability to fully engage in the study, as determined by the Principal Investigator
  • Current involvement in legal proceedings
  • Mental retardation or significant cognitive impairment
  • Significant suicidal ideation indicated by a BDI-II item 9 score ≥ 2 or enacted suicidal behaviors within 6 months prior to eligibility
  • Any concurrent psychotherapy of any duration
  • Inability to understand study procedures and participate in the informed consent process

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mobile mental health intervention
Participants will receive emotional support and problem-solving / stress-management skills via over-the-phone coaching sessions and mobile applications.
Participants receive three 30-minute phone sessions with a doctorate-level therapist over the course of one month. These sessions are skills-based and focus on improving participants' problem solving through cognitive-behavioral techniques. Participants are allowed to text the therapist between sessions for information and support.
Participants will have access to 3 mobile apps for the duration of the study, and after it ends. One app will push participants a daily, self-reflective survey to complete, and a daily motivational or instructional tip to rate. Other apps will provide education and exercises on various aspects of mental health and wellness, such as sleep and relaxation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment adherence
Time Frame: Baseline (week 0) to Endpoint (week 4)
Adherence will be assessed based on number of coaching sessions attended over the course of the 1 month treatment period (range of 0 to 3).
Baseline (week 0) to Endpoint (week 4)
Treatment satisfaction
Time Frame: Treatment endpoint (week 4)
Participants will be asked to report the extent to which they were satisfied with the study, the extent to which they thought the study was helpful, and whether they would recommend the study to someone else. These responses are recorded on 5-point likert type scales with higher ratings indicating higher satisfaction.
Treatment endpoint (week 4)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Depression symptoms
Time Frame: Baseline (week 0) to Endpoint (week 4)
Depression symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). The range is from 0-27. Higher values represent worse depression symptoms.
Baseline (week 0) to Endpoint (week 4)
Posttraumatic Stress Disorder symptoms
Time Frame: Baseline (week 0) to Endpoint (week 4)
PTSD symptoms will be assessed using the PTSD Checklist for DSM-5 (PCL-5). The range is from 0-80. Higher values represent worse PTSD symptoms.
Baseline (week 0) to Endpoint (week 4)
Emotion Regulation
Time Frame: Baseline (week 0) to Endpoint (week 4)
Ability to regulate emotion will be assessed using the Difficulties in Emotion Regulation Scale (DERS). Range is from 36 to 180. Higher scores suggest greater problems with emotion regulation.
Baseline (week 0) to Endpoint (week 4)
Anxiety symptoms
Time Frame: Baseline (week 0) to Endpoint (week 4)
Current symptoms of anxiety will be assessed using the State Anxiety scale of the State Trait Anxiety Inventory. Scores range from 20 to 80. Higher scores indicate greater anxiety.
Baseline (week 0) to Endpoint (week 4)
Risky sexual behavior and substance use
Time Frame: Baseline (week 0) to Endpoint (week 4)
Risky sexual behaviors and substance use will be assessed using the Centers for Disease Control and Prevention's Youth Risk Behavior Survey (2011).
Baseline (week 0) to Endpoint (week 4)
Acceptability of treatment components
Time Frame: Endpoint (week 4)
At the end of the treatment period, participants will rate the extent to which they liked each of the different treatment components (coaching sessions, text messages, apps, tips). Participants will also be asked to report the extent to which they used the skills that they learned in the coaching sessions.
Endpoint (week 4)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptability of mental health treatment
Time Frame: Baseline (week 0) to Endpoint (week 4)
Attitudes toward the mental health system will be assessed using an author-developed measure.
Baseline (week 0) to Endpoint (week 4)
Positive and negative affect
Time Frame: Baseline (week 0) to Endpoint (week 4)
Current positive and negative emotions will be assessed using the Positive and Negative Affect Schedule.
Baseline (week 0) to Endpoint (week 4)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alyson K Zalta, PhD, Rush University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 29, 2016

Primary Completion (Actual)

December 11, 2017

Study Completion (Actual)

May 11, 2018

Study Registration Dates

First Submitted

July 24, 2018

First Submitted That Met QC Criteria

August 6, 2018

First Posted (Actual)

August 8, 2018

Study Record Updates

Last Update Posted (Actual)

August 8, 2018

Last Update Submitted That Met QC Criteria

August 6, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 14112402

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mental Health

Clinical Trials on Coaching sessions

Subscribe